We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has issued a not approvable letter for Merck's Vioxx successor Arcoxia, telling the company it will require additional data to support the risk-benefit profile of the drug.